Home / Centerstage / 2014 / december / Week 1 /
Merck agrees to acquire Cubist Pharmaceuticals, a company specializing in developing treatments for "superbugs," for $9.5 billion. The acquisition demonstrates Merck's commitment to combating antibiotic-resistant bacteria, as Cubist Pharmaceuticals' expertise in this field aligns with Merck's efforts to address the growing global threat of drug-resistant infections.
Saturday, 6 December, 2014